Investors purchasing shares of Sellas Life Sciences Group (SLS) are typically speculating on the clinical success and future commercial potential of its proprietary immunotherapy treatments targeting acute myeloid leukemia and other refractory cancers. Positive clinical data readouts, orphan drug designations, and anticipated regulatory milestone updates from ongoing late-stage clinical trials act as major catalysts. Speculative biotech investors are drawn to the stock's high-beta profile, where successful trial results can trigger rapid share price appreciation.